For glycolysis-focused interventions, the DAPA-CKD study demonstrated that dapagliflozin (an SGLT2 inhibitor) significantly reduced the risk of substantial kidney function decline, end-stage renal disease, and renal or cardiovascular death in CKD patients, regardless of diabetes status [119]. This evidence concerns the gene SLC5A2 and diabetes mellitus.